# Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

> **NCT02730377** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 1991 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** liraglutide
- **DRUG:** alpha-glucosidase inhibitors
- **DRUG:** DPP-4 inhibitors
- **DRUG:** meglitinides
- **DRUG:** SGLT-2 inhibitors
- **DRUG:** sulphonylurea
- **DRUG:** thiazolidinediones

## Key facts

- **NCT ID:** NCT02730377
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-28
- **Primary completion:** 2019-08-05
- **Final completion:** 2019-08-12
- **Target enrollment:** 1991 (ACTUAL)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02730377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02730377, "Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02730377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*